This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The GTx Cancer Muscle-Wasting Drug Studies Will Fail. Here's Why

GTx announced top-line results from the enobosarm phase IIb study in June 2009. Note at that time, Merck (MRK - Get Report) was collaborating with GTx on enobosarm's development. (The drug was called Ostarine back then.)

In March 2010 (and after having the phase IIb cachexia data in hand) Merck decided to abandon Ostarine/enbosarm, handing rights to the drug back to GTx.

GTx has discussed and presented enobosarm data from the phase IIb study since 2009, but the full study was only published this past April in Lancet Oncology. (Adrian S. Dobs et al, Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind randomised controlled phase 2 trial.)

Read the Lancet Oncology paper very closely and what you'll discover is that the study was widely skewed in favor of enobosarm over placebo. Patients with more advanced disease or less muscle function at baseline were randomized disproportionately to the control (placebo) arm, which artificially elevated the effect of enobosarm.

A close read of the study also reveals that a good number of patients were outliers, meaning they performed either really well or really poorly on muscle function tests. Coincidentally or not, the study's endpoints were assessed using mean (average) values, not the median, which in this case, worked out incredibly well for enobosarm relative to placebo.

But when the effect of outlier patients is minimized by analyzing data using median values -- the more widely accepted method -- enobosarm's benefit over placebo disappears.

Take a look at this slide, which comes from GTx and depicts results from the phase IIb study isolated only for the non-small cell lung cancer patients. Remember, this is the group of cancer patients in which GTx says enobosarm had the most benefit, which is why the ongoing phase III studies are only enrolling lung cancer patients.

Sixty-one lung cancer patients were enrolled in this study out of 159 total, or 38 percent. But notice only half the enrolled lung cancer patients -- 31 to be exact -- were included in the efficacy analysis.

According to the Lancet Oncology article, there were 10 patients and 13 patients with lung cancer randomized to the placebo and 3 mg enobosarm arms of the study, respectively. This means GTx claims positive results for enobosarm in lung cancer based on data from 15% of patients in the phase IIb study.

Why would enobosarm work better against cachexia in lung cancer patients than in other forms of cancer? GTx hasn't offered an explanation but the Lancet Oncology paper shows clearly that the lung cancer patient subgroup was skewed in enobosarm's favor.
2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ZIOP $5.50 0.00%
CLSN $1.08 0.00%
GTXI $0.70 0.00%
MRK $48.85 0.00%
AAPL $93.70 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs